Debt-to-equity of Apellis Pharmaceuticals, Inc. from 30 Sep 2018 to 30 Sep 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Apellis Pharmaceuticals, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2018 to 30 Sep 2025.
Apellis Pharmaceuticals, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 276%, a 7.8% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

Apellis Pharmaceuticals, Inc. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q3 2025	276%	+20%	+7.8%	30 Sep 2025
Q2 2025	334%	+85%	+34%	30 Jun 2025
Q1 2025	291%	+68%	+31%	31 Mar 2025
Q4 2024	254%	+58%	+30%	31 Dec 2024
Q3 2024	256%	+57%	+28%	30 Sep 2024
Q2 2024	249%	+63%	+34%	30 Jun 2024
Q1 2024	223%	+28%	+14%	31 Mar 2024
Q4 2023	196%	-1%	-0.6%	31 Dec 2023
Q3 2023	199%	0%	-0.06%	30 Sep 2023
Q2 2023	186%	-93%	-33%	30 Jun 2023
Q1 2023	195%	-409%	-68%	31 Mar 2023
Q4 2022	197%	-5368%	-96%	31 Dec 2022
Q3 2022	200%	-4921%	-96%	30 Sep 2022
Q2 2022	279%	-1089%	-80%	30 Jun 2022
Q1 2022	604%	+130%	+27%	31 Mar 2022
Q4 2021	5565%	+5255%	+1694%	31 Dec 2021
Q3 2021	5120%	+4790%	+1450%	30 Sep 2021
Q2 2021	1369%	+1105%	+420%	30 Jun 2021
Q1 2021	474%	+259%	+121%	31 Mar 2021
Q4 2020	310%	+143%	+85%	31 Dec 2020
Q3 2020	330%	+240%	+264%	30 Sep 2020
Q2 2020	263%	+218%	+479%	30 Jun 2020
Q1 2020	214%	+188%	+703%	31 Mar 2020
Q4 2019	167%	+145%	+662%	31 Dec 2019
Q3 2019	91%	+70%	+332%	30 Sep 2019
Q2 2019	45%			30 Jun 2019
Q1 2019	27%			31 Mar 2019
Q4 2018	22%			31 Dec 2018
Q3 2018	21%			30 Sep 2018

* An asterisk sign (*) next to the value indicates that the value is likely invalid.